| Literature DB >> 29847670 |
Shruti Sharma1,2,3, Kathryn E Bollinger2,3, Sai Karthik Kodeboyina1, Wenbo Zhi1, Jordan Patton2, Shan Bai1, Blake Edwards2, Lane Ulrich2, David Bogorad2, Ashok Sharma1,4.
Abstract
Purpose: Primary open angle glaucoma (POAG) is the most prevalent form of glaucoma, accounting for approximately 90% of all cases. The aqueous humor (AH), a biological fluid in the anterior and posterior chambers of the eye, is involved in a multitude of functions including the maintenance of IOP and ocular homeostasis. This fluid is very close to the pathologic site and is also known to have a significant role in glaucoma pathogenesis. The purpose of this study was to identify proteomic alterations in AH from patients with POAG.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29847670 PMCID: PMC6733532 DOI: 10.1167/iovs.17-23434
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.799
Baseline Characteristics of Normal Controls and POAG Subjects
| Subjects, | 32 | 15 | NA |
| Female/male | 20/12 | 11/4 | 0.688 |
| Age, y | 65.8 ± 9.1 | 65.1 ± 14.3 | 0.855 |
| Age range, y | 48–82 | 35–83 | NA |
| Race: African American/ Caucasian | 15/17 | 8/7 | 0.920 |
| BMI | 29.8 ± 5.5 | 32.2 ± 7.8 | 0.387 |
| Hypertension, N/Y | 2/30 | 2/12 | 0.747 |
| Smoking, N/Y | 23/4 | 13/2 | 1.000 |
| Cardiovascular disease, N/Y | 28/4 | 12/1 | 1.000 |
| Cerebrovascular disease, N/Y | 29/3 | 13/ 0 | 0.628 |
| Collagen vascular disease, N/Y | 32/0 | 13/0 | NA |
| Diabetes, N/Y | 19/13 | 8/5 | 1.000 |
| Cup/disc ratio | 0.27 | 0.62* | 3 × 10−4 |
| IOP | 13.8 ± 2.6 | 16.1 ± 6.9 | 0.223 |
NA, not available.
< 0.05.
AH Proteins Significantly Altered in Subjects With POAG
| 1 | Ig κ chain C region | A0A087X130 | 1.31 (1.065–1.609) | 0.0104 | 13.56 | |
| 2 | Inter-α-Trypsin Inhibitor heavy chain4 | B7Z544 | 1.64 (1.065–2.521) | 0.0248 | 4.10 | |
| 3 | Apolipoprotein C-III | A3KPE2 | 1.90 (1.181–3.048) | 0.0081 | 3.36 | |
| 4 | Isocitrate dehydrogenase [NAD] subunit α | H0YLI6 | 1.98 (1.141–3.434) | 0.0152 | 3.11 | |
| 5 | cDNA FLJ42083 fis, clone TCERX2000613 | Q6ZVM5 | 1.90 (1.033–3.508) | 0.0391 | 2.98 | |
| 6 | Serine/cysteine proteinase inhibitor clade F | C9JPV4 | 1.55 (1.046–2.304) | 0.0292 | 2.94 | |
| 7 | Niemann-Pick disease, type C2 | G3V2V8 | 1.99 (1.150–3.452) | 0.0139 | 2.88 | |
| 8 | Succinate-CoA ligase subunit β | B4DRV2 | 2.57 (1.147–5.752) | 0.0218 | 2.70 | |
| 9 | KIAA0100 | K7EQ86 | 2.62 (1.255–5.472) | 0.0103 | 2.29 | |
| 10 | CCR4-NOT transcription complex subunit 4 | B3KQ99 | 3.80 (1.421–10.171) | 0.0078 | 2.23 | |
| 11 | Aquaporin 4 | L0R6C7 | 3.63 (1.381–9.563) | 0.0090 | 2.11 | |
| 12 | Collagen, type XVIII, α 1 | Q8NG19 | 2.64 (1.030–6.756) | 0.0432 | 2.08 | |
| 13 | NACHT and WD repeat domain containing 1 | F8W0U9 | 2.09 (1.069–4.068) | 0.0312 | 2.07 | |
| 14 | Transmembrane protein 120B | H0YG77 | 1.59 (1.025–2.456) | 0.0383 | 2.06 | |
| 15 | Leucine rich repeat containing 34 | G3V115 | 2.40 (1.143–5.028) | 0.0207 | 1.98 | |
| 16 | IgGFc-binding protein | A0A087WUZ2 | 2.10 (1.114–3.966) | 0.0219 | 1.92 | |
| 17 | Na+/K+ Transporting ATPase Interacting 2 | B3KNZ0 | 2.07 (1.064–4.007) | 0.0321 | 1.92 | |
| 18 | Solute Carrier Family 35 Member C2 | B7Z6R4 | 2.29 (1.095–4.798) | 0.0278 | 1.89 | |
| 19 | Tetraspanin 14 | Q8N2P5 | 2.39 (1.107–5.151) | 0.0265 | 1.88 | |
| 20 | Family With Sequence Similarity 171, Member B | A0A087WU95 | 2.28 (1.092–4.758) | 0.0282 | 1.87 | |
| 21 | Fetuin-B | F8WEP7 | 2.22 (1.079–4.575) | 0.0303 | 1.86 | |
| 22 | LDL receptor-related protein-5 | E9PHY1 | 2.25 (1.069–4.725) | 0.0327 | 1.83 | |
| 23 | Fibrinogen β chain | D6REL8 | 1.93 (1.041–3.576) | 0.0368 | 1.82 | |
| 24 | Hydroxysteroid (17-β) Dehydrogenase 10 | Q5H928 | 2.43 (1.070–5.511) | 0.0339 | 1.80 | |
| 25 | Phosphatidylinositol glycan, class C | A0A024R900 | 2.06 (1.012–4.190) | 0.0464 | 1.78 | |
| 26 | Protein cornichon homolog 1 | G3V5P8 | 2.66 (1.173–6.048) | 0.0192 | 1.75 | |
| 27 | Torsin family 3, member A | A0A024R943 | 2.49 (1.142–5.448) | 0.0218 | 1.73 | |
| 28 | Mediator complex subunit MED23 | B9TX53 | 2.26 (1.113–4.590) | 0.0240 | 1.68 | |
| 29 | Succinate dehydrogenase assembly factor 2 | M0QY91 | 2.09 (1.089–4.004) | 0.0267 | 1.67 | |
| 30 | Protein COMMD3-BMI1 | Q5T8Z1 | 2.05 (1.016–4.149) | 0.0452 | 1.64 | |
| 31 | Inositol polyphosphate 1-phosphatase | C9J128 | 2.12 (1.044–4.302) | 0.0376 | 1.59 | |
| 32 | cDNA FLJ57526 | N/A | B4DLF2 | 2.00 (1.036–3.839) | 0.0388 | 1.54 |
| 33 | Rheumatoid factor D5 light chain | A0N5G5 | 2.36 (1.030–5.406) | 0.0424 | 1.46 |
Figure 1Box plots showing distribution of relative protein abundance in the AH from subjects with POAG (n = 15) and control subjects without POAG undergoing cataract surgery (n = 32). FC represents the ratios between the mean levels in POAG and control groups for each protein.
Figure 2ROC curves of the top more abundant proteins in POAG. AUC values represent the significance of the AH proteins as POAG biomarkers.
Figure 3The risk of POAG in subjects with different protein quartiles. Individual protein levels were used to assess the OR of having POAG at different protein levels. All subjects were divided into four quartiles (Q1–Q4) based on protein levels. The first quartile (Q1) was used as reference, and ORs of having POAG was calculated for upper three quartiles. Analyses using quartiles revealed that risk of POAG increases with increasing levels of these proteins. The open bar represents the first quartile as reference (OR = 1). From left to right, each of the other three solid bars represent second to fourth quartiles (Q2–Q4).
Biological Functions and Pathways Significantly Enriched in Proteins Associated With POAG
| Uniprot keywords | ||
| Signaling pathways proteins | 15 | 4.1 × 10−4 |
| Glycoprotein | 15 | 1.1 × 10−3 |
| Secreted proteins | 10 | 4.2 × 10−4 |
| Disease mutation | 9 | 1.2 × 10−2 |
| Protease inhibitor | 3 | 8.5 × 10−4 |
| Uniprot sequence features | ||
| Glycosylation site: N-linked (N-GlcNAc) | 14 | 1.0 × 10−3 |
| Signal peptide | 13 | 3.6 × 10−4 |
| Disulfide bond | 9 | 1.8 × 10−2 |
| Glycosylation site: O-linked (O-GlcNAc) | 3 | 3.7 × 10−4 |
| Cellular compartments | ||
| Extracellular exosome | 10 | 1.2 × 10−2 |
| Extracellular region | 8 | 3.6 × 10−3 |
| Blood microparticle | 4 | 1.1 × 10−4 |
| Mitochondrial matrix | 4 | 1.9 × 10−3 |
| External side of plasma membrane | 3 | 5.1 × 10−3 |
| Biological processes | ||
| Negative regulation of endopeptidase activity | 3 | 6.6 × 10−4 |
| Platelet degranulation | 3 | 4.1 × 10−4 |
| Cholesterol homeostasis | 3 | 1.0 × 10−4 |
| Molecular and cellular functions | ||
| Small molecule biochemistry | 8 | 9.9 × 10−5 |
| Lipid metabolism | 7 | 9.9 × 10−5 |
| Molecular transport | 7 | 9.9 × 10−5 |
| Cell death and survival | 6 | 7.4 × 10−4 |
| Vitamin and mineral metabolism | 5 | 4.0 × 10−4 |
| Canonical pathways | ||
| FXR/RXR activation | 4 | 2.5 × 10−5 |
| LXR/RXR activation | 3 | 6.0 × 10−4 |
| Acute phase response signaling | 3 | 1.6 × 10−3 |
| Intrinsic prothrombin activation pathway | 2 | 1.5 × 10−3 |
| Coagulation pathway | 2 | 1.0 × 10−3 |
Figure 4Network analysis using IPA was performed to search for defined interactions between 33 proteins associated with POAG. Each protein is represented as a node, and an edge represents an interaction between two nodes. Red nodes indicate more abundant proteins, whereas white nodes are proteins not significantly altered in POAG but are required for network stability. A solid line represents direct functional interaction. An arrow indicates action of a protein product on a target. Circular arrow indicates a self-referential relationship. Proteins are separated based on their cellular compartments.